Blog

Posted by Michael Wonder on 27 Jun 2025

Xtandi (enzalutamide) now funded in Ontario for all approved prostate cancer indications

26 June 2025 - Today, Astellas Pharma Canada announced that Xtandi (enzalutamide) is now funded by the Ontario Drug Benefit Program ...

Posted by Michael Wonder on 30 Sep 2023

Medison Pharma announces public formulary listing of Qinlock (ripretinib) in Canadian provinces: Ontario and Quebec for advanced gastro-intestinal stromal tumour treatment

29 September 2023 - Medison Pharma is pleased to announce the public formulary listing of Qinlock in Canadian provinces: Ontario ...

Posted by Michael Wonder on 10 Dec 2020

Ontario to begin vaccinations next week in Toronto, Ottawa

10 December 2020 - The first vaccines will go to health care workers at long-term care homes and other high-risk ...